 |
 |
 |
 |
 |
 |
 |
 |
E-Mail
ShareNNRTIs in Development
- TMC278 (Rilpivirine) Stands Up to Efavirenz in Battle of First-Line NNRTIs; FDA Approval May Be Drawing Near: A Blog Entry by Myles Helfand (July 28, 2010)
In The XVIII International AIDS Conference, from The Body PRO - TMC278 Noninferior to Efavirenz in Naive But With More Virologic Failures (July 22, 2010)
From National AIDS Treatment Advocacy Project - Peering in the Pipeline (Summer 2009)
To read PDF, click here.
In Achieve, from ACRIA and GMHC - Two NNRTIs in Early Development Show Promising Results (August 7, 2008)
From Project Inform - TMC278 Nanosuspension Found Long-Acting, Well-Tolerated in First Trial in HIV-Uninfected Subjects (August 5, 2008)
In The XVII International AIDS Conference, from The Body PRO - TMC278 (Rilpivirine) Efficacy, Toxicity and Pharmacokinetics (July 24, 2007)
In The 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, from The Body PRO - An Alternative NNRTI, TMC278, Progresses in Development (February 28, 2007)
In Exclusive Coverage of the 14th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - NNRTIs in Development (March 30, 2006)
An overview from Edwin DeJesus, M.D.
From The Body - BILR 355 BS, a Second-Generation NNRTI, Shows Activity Against Most Common NNRTI Mutations (December 17, 2005)
[Archived Article]
In The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy - GW695634 Demonstrates Potent Activity in 7-Day Monotherapy Study in an NNRTI Treatment-Experienced Population (July 27, 2005)
[Archived Article]
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment - Pfizer Discontinues Development of Capravirine, for HIV/AIDS (July 1, 2005)
[Archived Article]
From Pfizer, Inc. - Early Pre-Clinical Development of GW8248 Promising (September 14, 2003)
[Archived Article]
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO - Non-Nucleoside Reverse Transcriptase Inhibitors (Summer/Autumn 2002)
[Archived Article]
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation
The Body PRO is a service of Body Health Resources Corporation, 250 West 57th Street, New York, NY 10107. The Body PRO and its logos are trademarks of Body Health Resources Corporation, which owns the copyright of The Body PRO's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body PRO is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body PRO should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.